Syndax Pharmaceuticals (SNDX)
(Delayed Data from NSDQ)
$21.28 USD
+0.22 (1.04%)
Updated Apr 29, 2024 03:59 PM ET
After-Market: $21.33 +0.05 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SNDX 21.28 +0.22(1.04%)
Will SNDX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SNDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNDX
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
SNDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know
Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know
Other News for SNDX
Syndax price target lowered by $3 at Citi, here's why
Buy Rating Reaffirmed for Syndax Pharmaceuticals on Strong Drug Pipeline and Strategic Partnerships
First Week of June 21st Options Trading For Syndax Pharmaceuticals (SNDX)
Syndax management to meet with BTIG
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum